Patents
Literature
Patsnap Copilot is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Patsnap Copilot

325results about How to "Suitable for manufacture" patented technology

Thin film deposition apparatus, method of manufacturing organic light-emitting display device by using the thin film deposition apparatus, and organic light-emitting display device manufactured by using the method

A thin film deposition apparatus that is suitable for manufacturing large-sized display devices on a mass scale and that can be used for high-definition patterning, a method of manufacturing an organic light-emitting display device by using the thin film deposition apparatus, and an organic light-emitting display device manufactured by using the method. The thin film deposition apparatus includes: a deposition source that discharges a deposition material; a deposition source nozzle unit disposed at a side of the deposition source and including a plurality of deposition source nozzles arranged in a first direction; a patterning slit sheet disposed opposite to the deposition source nozzle unit and including a plurality of patterning slits arranged in the first direction; a first barrier plate assembly including a plurality of first barrier plates that are disposed between the deposition source nozzle unit and the patterning slit sheet in the first direction, and that partition a space between the deposition source nozzle unit and the patterning slit sheet into a plurality of sub-deposition spaces; and a second barrier plate disposed at one side of the patterning slit sheet, wherein an inner part of the second barrier plate is partitioned into a plurality of spaces by a plurality of barrier ribs.
Owner:SAMSUNG DISPLAY CO LTD

Multi-Component Medicine Evaluation Method

A method for evaluation of a multi-component medicine comprising judging the degree of difference of the multi-component medicine to be evaluated from a group of multi-component medicines selected as a reference group by using a Mahalanobis distance obtained by a process comprising the following steps (1) to (8),
    • (1) a step of obtaining fingerprint data of three-dimensional high performance liquid chromatography of the multi-component medicine to be evaluated,
    • (2) a step of combining the fingerprint data obtained in (1) with fingerprint data of three-dimensional high performance liquid chromatography of other multi-component medicines of the same kind forming a reference group,
    • (3) a step of allocating variable axes in the MT method to the number of multi-component medicine and either the elution time or detection wavelength of the fingerprint data of (2) above and regarding a signal strength as a characteristic amount in the MT method,
    • (4) a step of obtaining a unit space from the characteristic amount of (3) using the MT method,
    • (5) a step of obtaining the Mahalanobis distance of all multi-component medicines for each detection wavelength or elution time using the MT method from the unit space obtained in (4),
    • (6) a step of allocating variable axes in the MT method to the number of the multi-component medicine and either the elution time or detection wavelength to which the variable axes are not allocated in the step (3) and regarding the Mahalanobis distance obtained in step (5) as a characteristic amount in the MT method,
    • (7) a step of obtaining a second unit space from the characteristic amount of (6) using the MT method, and
    • (8) a step of obtaining the Mahalanobis distance of the multi-component medicine to be evaluated using the MT method from the second unit space obtained in (7).
According to the present invention, because the waveform processing of HPLC peaks is unnecessary, dispersion among data are small, thereby bringing highly reliable results; because the amount of information (the number of data points) is not limited to the number of peaks of a specific component, the amount of information can be freely increased or decreased; in addition, because it is not necessary to judge by combining the value of the content of two or more components, but can be judged using a single numerical value, the degree of difference of the multi-component medicine to be evaluated from a reference group can be simply judged.
Owner:TSUMURA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products